Impaired mitochondrial energy metabolism as a novel risk factor for selective onset and progression of dementia in oldest-old subjects

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 565-574

  Zhao, Wei ^a,b   Wang, Jun ^a,b   Varghese, Merina ^a   Ho, Lap ^a,b   Mazzola, Paolo ^a,c   Haroutunian, Vahram ^a,b   Katsel, Pavel L ^a,b   Gibson, Gary E ^d   Levine, Samara ^a   Dubner, Lauren ^a   Pasinetti, Giulio Maria ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Alzheimer disease; Dementia; Energy metabolism; Mitochondria; Neuropathology

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CITRIC ACID CYCLE; CONTROLLED STUDY; DISEASE COURSE; ENERGY METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MALE; MICROARRAY ANALYSIS; MITOCHONDRIAL RESPIRATION; POLYMERASE CHAIN REACTION; RISK FACTOR;

EID: 84929174572     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S74898     Document Type: Article

References (40)

1. Kawas CH. The oldest old and the 90+ Study. Alzheimers Dement. 2008;4(1 Suppl 1):S56–S59.
2. Haroutunian V, Schnaider-Beeri M, Schmeidler J, et al. Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol. 2008;65(9):1211–1217.
3. Prohovnik I, Perl DP, Davis KL, Libow L, Lesser G, Haroutunian V. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology. 2006;66(1):49–55.
4. Corrada MM, Brookmeyer R, Berlau D, Paganini-Hill A, Kawas CH. Prevalence of dementia after age 90: results from the 90+ study. Neurology. 2008;71(5):337–343.
5. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119–1122.
6. von Strauss E, Viitanen M, De Ronchi D, Winblad B, Fratiglioni L. Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol. 1999;56(5):587–592.
7. Ebly EM, Parhad IM, Hogan DB, Fung TS. Prevalence and types of dementia in the very old: results from the Canadian Study of Health and Aging. Neurology. 1994;44(9):1593–1600.
8. Blass JP, Sheu KF, Cooper AJ, Jung EH, Gibson GE. Thiamin and Alzheimer’s disease. J Nutr Sci Vitaminol (Tokyo). 1992; Spec No: 401–404.
9. Roze E, Saudou F, Caboche J. Pathophysiology of Huntington’s disease: from huntingtin functions to potential treatments. Curr Opin Neurol. 2008;21(4):497–503.
10. Markesbery WR, Carney JM. Oxidative alterations in Alzheimer’s disease. Brain Pathol. 1999;9(1):133–146.
11. Smith CD, Carney JM, Tatsumo T, Stadtman ER, Floyd RA, Markesbery WR. Protein oxidation in aging brain. Ann N Y Acad Sci. 1992;663:110–119.
12. Cecarini V, Ding Q, Keller JN. Oxidative inactivation of the proteasome in Alzheimer’s disease. Free Radic Res. 2007;41(6):673–680.
13. Butterfield DA, Reed TT, Perluigi M, et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer’s disease. Brain Res. 2007;1148:243–248.
14. Sultana R, Reed T, Perluigi M, Coccia R, Pierce WM, Butterfield DA. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J Cell Mol Med. 2007;11(4):839–851.
15. Pamplona R, Dalfo E, Ayala V, et al. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem. 2005;280(22):21522–21530.
16. Sharov VS, Galeva NA, Dremina ES, Williams TD, Schoneich C. Inactivation of rabbit muscle glycogen phosphorylase b by peroxynitrite revisited: does the nitration of Tyr613 in the allosteric inhibition site control enzymatic function? Arch Biochem Biophys. 2009;484(2):155–166.
17. Marcondes S, Turko IV, Murad F. Nitration of succinyl-CoA: 3-oxoacid CoA-transferase in rats after endotoxin administration. Proc Natl Acad Sci U S A. 2001;98(13):7146–7151.
18. Souza JM, Choi I, Chen Q, et al. Proteolytic degradation of tyrosine nitrated proteins. Arch Biochem Biophys. 2000;380(2):360–366.
19. Katsel P, Tan W, Haroutunian V. Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. PLoS One. 2009;4(10):e7642.
20. Haroutunian V, Katsel P, Schmeidler J. Transcriptional vulnerability of brain regions in Alzheimer’s disease and dementia. Neurobiol Aging. 2009;30(4):561–573.
21. Rokosh DA, Kurz WG, LaRue TA. A modification of isocitrate and malate dehydrogenase assays for use in crude cell free extracts. Anal Biochem. 1973;54(2):477–483.
22. Trounce IA, Kim YL, Jun AS, Wallace DC. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 1996;264:484–509.
23. Barrientos A. In vivo and in organello assessment of OXPHOS activities. Methods. 2002;26(4):307–316.
24. Chen X, Stern D, Yan SD. Mitochondrial dysfunction and Alzheimer’s disease. Curr Alzheimer Res. 2006;3(5):515–520.
25. de la Torre JC. Pathophysiology of neuronal energy crisis in Alzheimer’s disease. Neurodegener Dis. 2008;5(3–4):126–132.
26. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer’s disease. Ann N Y Acad Sci. 2008;1147:180–195.
27. Plum F, Posner JB. The diagnosis of stupor and coma. Contemp Neurol Ser. 1972;10:1–286.
28. Sheu KF, Cooper AJ, Koike K, Koike M, Lindsay JG, Blass JP. Abnormality of the alpha-ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimer’s disease. Ann Neurol. 1994;35(3):312–318.
29. Sheu KF, Kim YT, Blass JP, Weksler ME. An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer’s disease brain. Ann Neurol. 1985;17(5):444–449.
30. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol. 2005;57(5):695–703.
31. Tumeh PC, Alavi A, Houseni M, et al. Structural and functional imaging correlates for age-related changes in the brain. Semin Nucl Med. 2007;37(2):69–87.
32. Dunaway GA, Kasten TP. Characterization of the rat heart 6-phosphofructo-1-kinase isozymes. J Mol Cell Cardiol. 1985;17(10):947–957.
33. Dunaway GA, Kasten TP. Nature of the rat brain 6-phosphofructo-1-kinase isozymes. J Biol Chem. 1985;260(7):4180–4185.
34. Lehninger AL, Nelson DL, Cox MM. Lehninger Principles of Biochemistry, New York, NY: W. H. Freeman; 2005.
35. Gibson GE, Karuppagounder SS, Shi Q. Oxidant-induced changes in mitochondria and calcium dynamics in the pathophysiology of Alzheimer’s disease. Ann N Y Acad Sci. 2008;1147:221–232.
36. Shi Q, Gibson GE. Oxidative stress and transcriptional regulation in Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(4):276–291.
37. Craft S. Insulin resistance syndrome and Alzheimer’s disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging. 2005;26(Suppl 1):65–69.
38. Beeri MS, Schmeidler J, Silverman JM, et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology. 2008;71(10):750–757.
39. Budhraja V, Spitznagel E, Schaiff WT, Sadovsky Y. Incorporation of gene-specific variability improves expression analysis using high-density DNA microarrays. BMC Biol. 2003;1:1.
40. Mariani TJ, Budhraja V, Mecham BH, Gu CC, Watson MA, Sadovsky Y. A variable fold change threshold determines significance for expression microarrays. FASEB J. 2003;17(2):321–323.